Search

Researchers from Shaanxi University of Technology conducted a study on the protective effects of Chlorogenic acid (CGA) against reproductive damage induced by Cyclophosphamide (CP) in male mice. The study found that CGA increased hormone levels, reduced oxidative stress, and improved sperm quality in testicular cells. The research concluded that CGA has a protective impact on testicular injuries caused by CP in mice. [Extracted from the article]

A report from the University of Western Australia discusses the use of tranexamic acid (TXA) in vascular surgery as part of the POISE-3 trial. The study aimed to assess the efficacy and safety of TXA in patients undergoing vascular surgery compared to non-vascular surgery. Results showed that while there were higher rates of bleeding and cardiovascular events in vascular surgery patients, there was no significant difference in the effects of TXA based on the type of surgery. The study concluded that the overall POISE-3 trial provides the best estimate of the effects of TXA for all patients, including those undergoing vascular surgery. [Extracted from the article]

A recent study conducted at Southeast University in Jiangsu, China, focused on the efficacy and safety of Tranexamic Acid (TXA) in elderly patients with femoral neck fractures undergoing hip arthroplasty. The meta-analysis included randomized controlled trials and cohort studies, showing that TXA significantly reduced the rate of blood transfusion, total blood loss, and postoperative hemoglobin drop without increasing thromboembolic complications. Both intravascular and topical administration of TXA were found to be effective in reducing perioperative transfusion rates in elderly patients with femoral neck fractures. [Extracted from the article]

A clinical trial, NCT06657924, aims to assess the effectiveness of preoperative tranexamic acid (TXA) in reducing bleeding during and after major colorectal surgery. The trial will compare the use of TXA to no TXA and evaluate its impact on bleeding complications and thromboembolic events within 30 days post-surgery. Participants receiving TXA will be administered 1g intravenously at the beginning and end of surgery. The trial is set to enroll 394 participants and is expected to be completed by May 1, 2026. [Extracted from the article]

Researchers from the Department of Orthopedics conducted a systematic review and meta-analysis on the effectiveness and safety of prehospital tranexamic acid (TXA) in trauma patients. The study included 11,259 patients from 11 studies and found that prehospital TXA reduced 24-hour and 28-30-day mortality rates and blood transfusions but increased the risks of infection and thromboembolism. The researchers recommend future randomized controlled trials with larger and more homogeneous samples to further validate these results. [Extracted from the article]

A clinical trial, NCT06665594, is being conducted to investigate the impact of tranexamic acid (TXA) on reducing bruising, swelling, and pain after hyaluronic acid (HA) filler injections on the face. Participants will receive either HA or HA+TXA injections on different sides of their face to compare the effects. The study aims to assess bruising intensity, duration, swelling, pain, and overall satisfaction through participant surveys, physician evaluations, and medical records review. The trial is set to be completed by December 31, 2025, with 40 participants enrolled. [Extracted from the article]

A recent study conducted at the Ottawa Hospital in Canada examined the use of tranexamic acid (TXA) during radical cystectomy surgeries for bladder cancer patients. The study aimed to determine if TXA could reduce the need for red blood cell transfusions post-surgery. However, the results showed that TXA did not significantly decrease the number of transfusions required, leading researchers to not recommend routine use of TXA during these surgeries. This research was supported by the Canadian Institutes of Health Research (CIHR) and was published in JAMA Surgery. [Extracted from the article]

Northwestern University conducted a study on the use of closed suction drainage after total knee arthroplasty with intravenous tranexamic acid administration. The research aimed to investigate the incidence of postoperative transfusion and return to the operating room for hemarthrosis in patients undergoing total knee arthroplasty with drains and IV tranexamic acid. The study found that postoperative drain use with IV tranexamic acid was safe and effective, with a low risk of postoperative transfusion and a low rate of hemarthrosis. The research has been peer-reviewed and published in The Journal of Knee Surgery. [Extracted from the article]

A recent study conducted in five Sub-Saharan African countries evaluated the feasibility and acceptability of integrating heat-stable carbetocin and tranexamic acid for the prevention and management of postpartum hemorrhage, following World Health Organization recommendations. The study found that both medicines were safely and appropriately implemented in primary and tertiary facilities, with high confidence and favorability from healthcare providers. The research suggests that dedicated training and regular supervision are essential for the continued safe use of these medicines, which hold promise for improving postpartum hemorrhage care in low- and middle-income countries. [Extracted from the article]

A recent study conducted by researchers at the University of Technology in Sydney, Australia, focused on the use of heat-stable carbetocin (HSC) and tranexamic acid (TXA) in preventing and treating postpartum hemorrhage (PPH) in humanitarian settings. The study involved 64 healthcare providers in South Sudanese and Ugandan facilities, who expressed positive views on the effectiveness of HSC and TXA in managing PPH. The findings highlighted the importance of ongoing education, clear guidelines, and comprehensive strategies to improve maternal health outcomes in resource-limited and fragile contexts. The study underscores the potential global implications of integrating HSC and TXA into PPH intervention packages. [Extracted from the article]

A study conducted at Nanjing Medical University in China explored the use of a novel coating on titanium surfaces to enhance the success of titanium implants in diabetic patients. The coating, composed of chlorogenic acid and strontium, showed promising results in improving cell adhesion, proliferation, and osteogenic potential in a high-glucose environment. The research suggests that this coating may be a valuable strategy for modifying titanium implants to withstand high-glucose conditions, potentially benefiting patients with diabetes. [Extracted from the article]

Researchers at Xiamen University of Technology in China have developed a new method for creating active inner coatings for food packaging using polyvinyl alcohol (PVA) reinforced with chlorogenic acid and functionalized layered clay. The study found that incorporating 3 wt% of layered clay enhanced the antioxidant, antibacterial, and UV absorption properties of the coating. This innovative approach aims to improve the effectiveness and stability of active functions in food packaging applications, particularly in constructing polylactic acid (PLA) three-layer active films. [Extracted from the article]

The article discusses a study conducted at the University of Technology in Uganda on implementing heat-stable carbetocin and tranexamic acid for postpartum hemorrhage prevention and treatment in humanitarian settings. The study involved a capacity-strengthening package for providers in basic obstetric care clinics, resulting in increased utilization of heat-stable carbetocin and moderate adoption of tranexamic acid. The research emphasizes the importance of continuous capacity development and cold-chain strengthening to ensure the quality of medications used in postpartum hemorrhage management. [Extracted from the article]

A study conducted at the University of Hawaii Manoa examined the impact of the 2017 Revised Japanese Obstetric Hemorrhage Management Guidelines on the use of tranexamic acid in patients undergoing cesarean deliveries. The research found that there was a significant increase in the rate of tranexamic acid administration following the implementation of the revised guidelines, reversing a previously observed downward trend. However, this increase did not result in fewer blood transfusions for patients. The study analyzed data from 91,166 cesarean deliveries in Japan from April 2012 to August 2021, sourced from the nationwide health insurance claims database. [Extracted from the article]

A preprint abstract discusses an exploratory randomized trial of tranexamic acid (TXA) to reduce postoperative delirium in adults undergoing lumbar fusion surgery. The study found that TXA did not significantly decrease delirium incidence compared to a placebo group, but there was a potential 33% relative decrease in delirium incidence that warrants further investigation in a larger clinical trial. The findings suggest that TXA may have an impact on delirium severity in relation to certain biomarkers, highlighting the need for more research in this area. [Extracted from the article]

Researchers at Shaqra University in Saudi Arabia have developed a new method for assessing tranexamic acid (TRX) using o-phthalaldehyde as a fluorogenic probe. TRX is used to manage various conditions such as heavy menstrual periods, hemophilia, and postpartum hemorrhage. The method was found to be effective, simple, and quick, making it a potential replacement for TRX assays in clinical trials and quality control. [Extracted from the article]

A recent pilot study conducted at Queen's University explored the use of tranexamic acid (TXA) to prevent delayed post-polypectomy bleeding (DPPB) after endoscopic mucosal resection of large colorectal polyps. The study involved 25 patients who received TXA post-procedure, with no major adverse events reported. While the findings suggest that TXA may be feasible in reducing DPPB, further randomized controlled studies are needed to confirm its effectiveness. The study was published in the Journal of the Canadian Association of Gastroenterology. [Extracted from the article]

Researchers at Arak University of Medical Sciences conducted a study comparing the short-term outcomes of vasopressin and tranexamic acid in acute gastrointestinal bleeding. The study involved 120 patients and found that the concurrent use of tranexamic acid and vasopressin improved renal function, stopped bleeding, and reduced the risk of re-bleeding, blood transfusion, and the need for endoscopic and surgical intervention. Further research is needed to determine the long-term effects of this treatment approach. The study was published in the Tehran University Medical Journal. [Extracted from the article]

Researchers from the Shanghai University of Traditional Chinese Medicine conducted a study on the role of early growth response-1 (EGR1) in promoting liver repair and regeneration after acetaminophen-induced liver injury. The study found that EGR1 deficiency worsened liver injury and delayed regeneration, while chlorogenic acid (CGA) promoted liver repair by enhancing EGR1 activation. The research, funded by various organizations, concluded that EGR1 is crucial for liver regeneration post liver injury, and CGA can aid in this process. [Extracted from the article]

Researchers at Oregon Health & Science University have conducted a study on Tranexamic acid (TXA), an antifibrinolytic drug used in traumatic hemorrhage and brain injury. The study aimed to identify research priorities related to TXA in trauma by analyzing questions from expert panels. The research highlighted the need for future funded studies to prioritize key topics identified in the questions. This peer-reviewed study provides valuable insights into the optimal use of TXA in trauma care. [Extracted from the article]

A study conducted at the RIKEN Center for Brain Science in Wako, Japan, focused on the treatment of Wasting Marmoset Syndrome (WMS) in captive common marmoset colonies. The research introduced a modified treatment method involving tranexamic acid therapy with supportive measures, which showed comparable efficiency to the original treatment. The study was supported by the Japan Agency for Medical Research and Development (AMED) under the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) project. For more information, readers can refer to the Journal of Visualized Experiments, where the research findings were published. [Extracted from the article]

A study conducted in Belfort, France, evaluated the effects of a single intraarticular injection of a HA/TXA conjugate on knee osteoarthritis in mice. The research found that the HA/TXA treatment showed greater efficacy in reducing pain and slowing OA progression compared to saline and HA alone. The study concluded that both HA and HA/TXA exhibited chondroprotective effects in the murine model of osteoarthritis. [Extracted from the article]

A patent application titled "Borate Complexes Of Chlorogenic Acid And Uses Thereof" was published online by inventors from Morristown, NJ, on October 3, 2024. The application discusses the potential health benefits of coffee bean-derived phytochemicals, particularly chlorogenic acid, in preventing chronic diseases and managing obesity. It also explores the use of boron in promoting the growth of beneficial bacteria in the gut microbiota and its potential impact on microbiome health. The application outlines methods for producing compositions containing borate esters of chlorogenic acid and their applications in treating boron insufficiency in the microbiome. [Extracted from the article]

Researchers in Jabalpur, India, conducted a randomized clinical trial to evaluate the use of topical epinephrine with xylocaine and systemic tranexamic acid after axillary lymph node dissection in breast cancer patients. The study aimed to reduce seroma development and hospital stay, potentially eliminating the need for drainage post-surgery. The research findings suggest that this combined treatment approach could be a viable alternative to traditional drainage methods, offering similar seroma rates with shorter hospital stays. [Extracted from the article]

A study conducted at Mayo Clinic in Rochester, Minnesota, evaluated the use of tranexamic acid (TXA) for patients with extracapsular hip fractures to determine its impact on transfusion rates, blood loss, and complications. The research found that administering TXA at the time of hospital admission did not decrease transfusion rates or blood loss for these patients. The study included 128 patients and concluded that preoperative TXA did not reduce blood loss for geriatric patients with extracapsular hip fractures. [Extracted from the article]

A retrospective study conducted at the Affiliated Hospital of Jiaxing University in China evaluated the safety and efficacy of intravenous tranexamic acid (TXA) administration in elderly patients undergoing anterior cervical discectomy fusion (ACDF) for the treatment of cervical spondylosis. The study included 114 patients, with 53 in the TXA group and 61 in the control group. The results showed that TXA administration effectively reduced perioperative blood loss without affecting coagulation function or increasing the risk of complications. This study provides valuable insights into the use of TXA in ACDF surgery for elderly patients. [Extracted from the article]

A new report from the Department of Orthopaedics and Traumatology discusses the use of tranexamic acid (TXA) in orthopedic surgery. The study aimed to analyze the effects of prophylactic administration of TXA on operative time and the amount of blood transfused during open fixation of pelvis and acetabulum fractures. The research found that TXA reduced intraoperative bleeding and shortened the duration of surgery for pelvic fractures. The study suggests that TXA should be considered an essential tool for orthopedic surgeons in managing these types of fractures. [Extracted from the article]

A study conducted by researchers from the University of Chicago examined the use of tranexamic acid (TXA) in patients with traumatic brain injury. TXA is an antifibrinolytic drug that has been shown to reduce mortality in head injury cases. The study aimed to determine if the route of administration (intravenous or intraosseous) affected the total drug exposure of TXA. The researchers performed a retrospective analysis of data from the prehospital TXA for traumatic brain injury trial and concluded that further investigation is needed to fully understand the implications of TXA administration via intraosseous access. [Extracted from the article]

A recent study conducted by researchers at the George Washington School of Medicine and Health Sciences has found that oral tranexamic acid (TXA) is a safe and effective treatment for postinflammatory hyperpigmentation (PIH). PIH is a skin disorder characterized by abnormal and excessive pigment deposition resulting from inflammation and damage to the skin. The study reviewed relevant articles from 2000 to the present and found that all studies demonstrated significant improvement in PIH without significant adverse effects. This research suggests that oral TXA could be used for both prevention and treatment of PIH. [Extracted from the article]

A recent study conducted by researchers at the Guangdong Academy of Agricultural Sciences in China has explored the effects of chlorogenic acid (CGA) on the intestinal health of weaned piglets. CGA, a natural polyphenol with antioxidant and anti-inflammatory properties, was found to reduce the rate of diarrhea and improve the structure of the intestines in piglets. Additionally, CGA increased the abundance of beneficial bacteria in the gut and decreased markers of inflammation and oxidative stress. The study suggests that CGA enhances intestinal health by inhibiting the TLR4/NF-kB pathway and activating the Nrf2 pathway. [Extracted from the article]

A recent study conducted by Hiroshima University in Japan examined the use of tranexamic acid (TXA) in children with severe traumatic brain injury (TBI). The study analyzed data from 342 patients and found that TXA administration was not associated with increased mortality or poor neurological outcomes. However, the researchers concluded that further prospective clinical trials are needed to fully understand the effects of TXA in pediatric TBI cases. This study provides valuable insights into the potential use of TXA in treating brain injuries in children. [Extracted from the article]

A systematic review and meta-analysis conducted by the University of Western Australia examined the use of tranexamic acid (TXA) in pediatric adenotonsillectomy (AT) procedures. The review analyzed eight studies and found that intravenous TXA did not significantly reduce perioperative bleeding in pediatric patients undergoing AT. However, when topical TXA was used intraoperatively during adenoidectomy alone, there was a significant reduction in both intraoperative blood loss and postoperative bleeding. The study suggests that TXA is safe and well-tolerated in the pediatric population, but further research is needed to investigate its risks and benefits in AT procedures. [Extracted from the article]

A recent study conducted at Mashhad University of Medical Sciences in Iran investigated the use of intravenous tranexamic acid to control bleeding during external dacryocystorhinostomy (DCR) surgery under general anesthesia. The study included 70 patients with nasolacrimal duct obstruction who were randomly assigned to receive either tranexamic acid or a placebo. The results showed that the group receiving tranexamic acid had significantly less bleeding and shorter surgical time compared to the control group. The researchers concluded that intravenous tranexamic acid administration before DCR surgery can effectively control bleeding during the procedure. [Extracted from the article]

A recent study conducted by researchers in Geneva, Switzerland, has found that a topical cream and serum containing tranexamic acid, niacinamide, and vitamin C can effectively reduce facial hyperpigmentation in Caucasian patients. The study involved 22 participants who applied the cream and serum for 8 weeks, and significant improvements in hyperpigmented areas were observed. The treatment was well-tolerated, with no serious adverse effects recorded. Participants reported high satisfaction with improvements in skin hydration, luminosity, and a reduced appearance of dark spots. This combination of ingredients offers a promising alternative for individuals seeking to improve skin tone and reduce facial skin coloration imbalance. [Extracted from the article]

Researchers from the Laboratory of Molecular Nephrology in Genova, Italy, have conducted a study on the role of abscisic acid (ABA) in cardiomyocytes. The study found that overexpression of ABA hormone receptors LANCL1 and LANCL2 in rat H9c2 cardiomyocytes increased mitochondrial proton gradient, respiration, and vitality after hypoxia/reoxygenation. The researchers also discovered that the ABA/LANCL1-2 system controls reactive oxygen species (ROS) turnover in cardiomyocytes through the transcription factor ERRa. These findings suggest that targeting the ABA/LANCL system could improve mitochondrial function and resilience to oxidative stress in cardiomyocytes. [Extracted from the article]

A study conducted at Thomas Jefferson University in Philadelphia compared the effects of preoperative tranexamic acid (TXA) administered intravenously (IV) versus subcutaneously on postoperative ecchymosis and edema in patients undergoing bilateral upper eyelid blepharoplasty. The study found that patients who received TXA had significantly lower ecchymosis and edema scores on postoperative day 1 and day 7 compared to those who did not receive TXA. Patients treated with IV or subcutaneous TXA also experienced shorter operative times, reduced time to resuming activities of daily living, and higher satisfaction scores. The study suggests that IV dosing may be clinically superior to subcutaneous dosing, although statistical superiority was not definitively identified. [Extracted from the article]

A literature review conducted by researchers at the Robert Jones and Agnes Hunt Orthopaedic Hospital explores the use of tranexamic acid in reducing blood loss during hip and knee arthroplasty procedures in the UK. The review examines the existing literature on the topic and finds a consensus in favor of tranexamic acid as a safe and effective measure for reducing blood loss. The researchers highlight the prevalence of blood loss in arthroplasty and the need for strategies to minimize it. The full article can be accessed for free through the provided link. [Extracted from the article]

A recent systematic review and meta-analysis conducted by researchers at the West China Hospital of Sichuan University evaluated the efficacy and safety of tranexamic acid (TXA) in patients with pelvic and acetabular fractures undergoing open reduction and internal fixation (ORIF). The analysis included four randomized controlled trials with 179 patients. The results showed that TXA did not significantly reduce estimated blood loss, blood transfusion units, transfusion rates, or surgery duration. Additionally, there was no significant difference in thromboembolic events or other postoperative complications between the TXA and control groups. The study concludes that further investigation is needed to determine the role of TXA in this clinical setting. [Extracted from the article]

A study conducted by Mazandaran University of Medical Sciences in Sari, Iran compared the local effects of tranexamic acid and phenylephrine on bleeding during rhinoplasty. The study, which involved 98 patients, found that the amount of bleeding was lower in the phenylephrine group compared to the tranexamic acid group. The researchers recommend the use of phenylephrine in rhinoplasty surgery to reduce bleeding and improve the surgeon's vision. The study was published in the Caspian Journal of Internal Medicine. [Extracted from the article]